Objectives We sought to evaluate the association between obesity and response to anti-
tumor necrosis factor-α (TNF) agents, through a systematic review and meta-analysis …

New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom
control towards treat-to-target algorithms in order to optimize treatment results. The treatment …

Background Real‐life data on newer biological and biosimilar agents for moderate‐to‐
severe psoriasis are lacking. Objectives To examine safety, efficacy and time to …

Abstract Background and Aims Following induction/maintenance treatment in the UNITI/IM-
UNITI studies of ustekinumab for Crohn's disease, patients entered a long-term extension for …

This guideline is the second European Crohn's and Colitis Organisation [ECCO] evidence-
based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update …

Background Drug survival analysis of biologic agents in psoriasis is of extreme importance,
as it allows not only the evaluation of objective clinical outcomes (such as effectiveness and …

Background Patients with plaque psoriasis treated with biologic therapies need more
efficacious, safe and convenient treatments to improve quality of life. Risankizumab and …

Summary Background In Phase 3 studies of ustekinumab, a fully human monoclonal IL‐
12/23p40 antibody approved for moderate‐to‐severe Crohn's disease, patients entered a …

Objective Drug survival is an important proxy measure for effectiveness of treatments for
inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA) …

Psoriasis is a common disease, which has a considerable impact on the healthcare system.
Therefore, appropriate use of therapeutic resources is very important. Management of …